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Abu-Raya et al. Consensus Statement on Immunization During Pregnancy
Immunization during pregnancy has been recommended in an increasing number of
countries. The aim of this strategy is to protect pregnant women and infants from severe
infectious disease, morbidity and mortality and is currently limited to tetanus, inactivated
influenza, and pertussis-containing vaccines. There have been recent advancements in
the development of vaccines designed primarily for use in pregnant women (respiratory
syncytial virus and group B Streptococcus vaccines). Although there is increasing
evidence to support vaccination in pregnancy, important gaps in knowledge still exist and
need to be addressed by future studies. This collaborative consensus paper provides
a review of the current literature on immunization during pregnancy and highlights the
gaps in knowledge and a consensus of priorities for future research initiatives, in order to
optimize protection for both the mother and the infant.
Keywords: group B Streptococcus vaccines, influenza, maternal immunization, pertussis, pregnant women,
respiratory syncytial virus, tetanus
INTRODUCTION
Vaccination of pregnant women induces a vaccine-specific
immune response in the mothers and the transfer of vaccine-
specific antibodies via the placenta and breastmilk to directly
protect the infant during the first months of life from the targeted
pathogens (1, 2). The potential of maternal immunization
in protecting young infants was made evident by tetanus
vaccination during pregnancy contributing to the reduction in
incidence of neonatal tetanus (3). This has also become evident
by the decrease in the incidence of severe pertussis disease
in young infants in countries that have implemented pertussis
immunization programs in pregnancy (4–7).
During the last decade, an increasing number of countries
have included vaccines for pregnant women in their national
vaccination programs. Vaccination with tetanus-containing
vaccines in pregnancy has been recommended for years in most
low and middle -income countries (LMICs) (3), and pertussis
and influenza vaccination programs for pregnant women have
been more recently recommended in a number of high-income
countries (HICs) and LMICs (Figure 1) (8, 9). Moreover, the
prevention of respiratory syncytial virus (RSV) and group
B Streptococcus (GBS) infections in infants through maternal
vaccination has become a priority and a target for potential new
vaccine candidates in trials and development (10–12).
To optimize the protection offered to mothers and infants
by maternal immunization, several factors that can affect this
strategy must be better understood (Figure 2). The goal of
this consensus paper written by experts in infectious diseases,
vaccination and maternal immunization from different world
regions is to summarize current evidence in the field of
immunization during pregnancy and to highlight the knowledge
gaps and prioritize future research strategies in order to optimize
protection for the mother, fetus and the infant.
STUDY DESIGN
The main aim of this consensus paper is to discuss current
knowledge regarding immunization during pregnancy and
highlight the gaps that need to be addressed to ensure the highest
protection for both the mother and their infants. References
were identified through searches of PubMed for human studies
published in English using the terms “immunization” or
“vaccination” or “tetanus” or “tetanus disease” or “tetanus
vaccine” or “pertussis” or “Tdap” or “pertussis immunization” or
“pertussis vaccination” or “pertussis vaccine” or “Tdap vaccine”
or “Tdap immunization” or “influenza” or “influenza vaccines”
or “influenza immunization” or “maternal influenza vaccination”
or “influenza vaccines in pregnancy” or “RSV” or “respiratory
syncytial virus” or “GBS” or “GBS vaccine” or “Group B
streptococcus” and “pregnancy.” Articles resulting from these
searches and relevant references cited in those articles were
reviewed. References were also provided by authors. Outcomes
assessed were safety, immunogenicity, efficacy, and effectiveness
of immunization during pregnancy against tetanus, pertussis,
influenza, RSV, and GBS diseases. After the initial review, a
meeting was held in Italy to discuss the current literature and
knowledge gaps. A consensus on the content was reached after
multiple rounds of revision among the authors.
ETHICS IN VACCINE TRIALS DURING
PREGNANCY
Maternal immunization, and the use of medication in pregnancy
in general, have been a focus of ethical deliberations for decades.
Until recently, the ethical prevailing approach for immunization
during pregnancy was based on the precautionary principle,
which limits introduction of new intervention whose ultimate
effects are uncertain. This precautionary principle-centered
approach, combined with risk aversion among legal departments
of vaccine manufacturers, led to exclusion of pregnant women
from most vaccine trials for decades, leading to gaps in evidence
of vaccine safety and efficacy among pregnant women. With
an increasing focus on maternal immunization, there has been
reconsideration of relevant ethical paradigms resulting in several
recent developments in this area.
First, a report of the U.S. National Vaccine Advisory
Committee’s Working Group on Maternal Immunization
Frontiers in Immunology | www.frontiersin.org 2 June 2020 | Volume 11 | Article 1282
Abu-Raya et al. Consensus Statement on Immunization During Pregnancy
FIGURE 1 | Countries with recommendations for immunization against pertussis in pregnancy by official authorities (for South America, pertussis immunization during
pregnancy is recommended by The Pan American Health Organization). This figure was inspired by G. Amirthalingham and K. Maertens and created by K. Maertens.
recommended that “Relevant regulations, statutes, and
policies. . . should be modified to indicate that pregnant
women are not a vulnerable population for the purposes of
ethical review” (13). This recommendation and concurrent
policy action led to a change in the U.S. Code of Federal
Regulations which had previously classified pregnant women
as being inherently vulnerable to coercion (14). Second,
recognizing that conventional paradigms often treated the risks
and benefits of maternal immunization to mothers and infants
as independent entities, a maternal interest-based paradigm
was proposed by Chamberlain et al. (15). This paradigm
recognizes the legitimacy of maternal interests in protecting
their infants and the legitimacy of her taking measures that
benefit only the fetus/newborn even if such measures do not
have direct benefits for the mother herself. The third major
development was creation of the Pregnancy Research Ethics
for Vaccines, Epidemics, and New Technologies (PREVENT)
working group. This multidisciplinary, international team of
17 experts developed a roadmap for inclusion of the interests
of pregnant women in the development and deployment of
vaccines (16). The underlying goal of these recommendations
was to ensure that pregnant women’s inclusion in vaccine
trials is the default position and that any exclusions need to be
justified rather than justifications being needed for inclusion of
pregnant women.
Globally, a progress has also been made in the prioritization
of immunization in pregnancy and the inclusion of pregnant
women in vaccine trials. The WHO Strategic Advisory Group
of Experts on Immunization (SAGE) recommended in 2012
that pregnant women should be highly prioritized for influenza
vaccination in countries that consider initiating or expanding of
seasonal influenza vaccine programs (17). In 2015, SAGE further
emphasized the importance of the platform of immunization in
pregnancy, as well the need to strengthen the delivery of vaccines
administered during pregnancy (18).
These and other developments in ethical considerations
for maternal immunization are likely to result in a more
conducive environment for maternal immunization research and
deployment. However, there are a few areas that require further
deliberations (Table 1).
SAFETY OF IMMUNIZATION DURING
PREGNANCY
Safety of vaccines administered during pregnancy needs to
be evaluated for both the mother and her newborn, and is
an important consideration for the mothers’ willingness to
receive a vaccine during pregnancy. There is a significant
bulk of evidence to support the safety of immunization with
tetanus toxoids (TT), the longest standing vaccine that is
recommended during pregnancy. There is also an increasing
body of evidence to support the safety of pertussis and influenza
immunization during pregnancy (see below specific sections).
However, continuous assessment and reporting of adverse
events after immunization during pregnancy remains important,
especially for relatively newly introduced maternal vaccines (e.g.,
pertussis), as it informs about rare events that might follow
immunization. In addition, assessment of baseline pregnancy
outcomes in unvaccinated women in different world regions
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FIGURE 2 | A summary of the major factors affecting vaccination in pregnancy. Created by Claudio Rosa.
and settings will help in establishing baselines to assess safety
outcomes against.
Furthermore, there is significant heterogeneity and lack of
consensus on adverse event reporting in maternal immunization
studies. This is a challenge for comparing and pooling
data from different studies. In an attempt to overcome this
weakness, WHO and the Brighton Collaboration worked
together to provide written guidance on how to conduct
safety studies in the field of maternal immunization (19).
The initiative termed the Global Alignment of Immunization
Safety Assessment in Pregnancy (GAIA) project worked on
standardizing the assessment of safety of vaccines in pregnancy
with specific focus on LMICs (20). Specifically, this initiative
proposed systematic data collection, specific case definitions
of key obstetric and neonatal health outcomes, ontology of
key terms and a map of pertinent disease codes. More
recently, case definition and guidelines for data collection,
analysis and presentation has been proposed for neonatal
seizures, neurodevelopmental delay, chorioamnionitis and post-
partum endometritis and infection by the GAIA and Brighton
collaboration working groups (21–24). Future studies assessing
safety of immunization during pregnancy should use the
proposed terms and definitions. In addition, currently available
data on safety of vaccination in pregnancy is derived from
vaccines that were initially licensed in non-pregnant populations.
Future vaccine trials will likely assess vaccines intended to
be licensed primarily for use in pregnant women. This
further emphasizes the need to standardize reporting of safety
outcomes in maternal immunization trials. Thus, we recommend
following the GAIA and Brighton collaboration guidelines
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TABLE 1 | Ethics areas related to immunization during pregnancy that require
further deliberations.
Are there differential ethical considerations based on the gestational week of
vaccination?
How is acceptable risk defined in pregnancy?
Can countries justify mass deployment of vaccines for use during pregnancy
without an injury compensation program?
for assessment and reporting of safety outcomes in maternal
immunization trials.
KEY FACTORS THAT INFLUENCE
IMMUNOGENICITY AND
EFFICACY/EFFECTIVENESS OF
IMMUNIZATION DURING PREGNANCY
Immune Responses of Pregnant Women to
Vaccination
The immune system of a pregnant woman is adapted to allow
for the survival of the semi-allogeneic fetus. Serum estradiol
levels increase up to 500-fold during normal pregnancy (25),
and the interplay between sex hormones and the maternal
immune system in pregnancy is complex (Table 2). These
changes might lead to the assumption that there are differences
in immune responses to vaccines between healthy pregnant and
non-pregnant women potentially leading to a lower immune
response in pregnant women. However, studies comparing
immunogenicity of vaccines in pregnant and non-pregnant
women have generally not demonstrated decreased antibody
responses in pregnant women. This has been the case for TT
(40) and for the pertussis antigens in the combined tetanus,
diphtheria, and acellular pertussis vaccine (Tdap) (41). However,
results for influenza vaccines have been less consistent. Some
studies carried out with influenza vaccines, including both the
pandemic H1N1/2009 (pH1N1/2009) monovalent inactivated
vaccine (MIV) and seasonal trivalent inactivated vaccine (TIV)
preparations, show similar hemagglutination inhibition (HAI)
seroconversion rates and antibody titers in pregnant and
non-pregnant women (42–44). Other studies showed lower
seroconversion rates and lower HAI geometric mean titers after
vaccination of pregnant womenwhen compared to non-pregnant
women (45–47).
The effect of maternal immunization on cellular immunity
has been less studied limiting conclusions. Proliferative and
interferon-γ responses to the Bordetella pertussis (B. pertussis)
antigens pertussis toxin (PT) 1 month after receipt of Tdap
vaccine were not significantly different in pregnant and non-
pregnant women andwere comparable in both after 1 year (41). A
small study showed that Natural killer cell and T-cell responses to
inactivated influenza vaccination (IIV) were higher in a pregnant
women compared to non-pregnant women (48).
TABLE 2 | Key changes in maternal adaptive immune system during pregnancy.
Main changes References
Lower B cell levels in pregnant women compared with
non-pregnant women
(26)
B cell lymphopenia in the third-trimester of pregnancy (25)
Estrogen reduces B cell lymphopoiesis during pregnancy (27, 28)
Decrease in B cell function (29)
Decreased total IgG levels, especially during late pregnancy (30, 31)
High estradiol levels promote T helper 2 cell responses (32–34)
Elevated progesterone during pregnancy inhibits T helper 1 cell
immune responses
(35)
A progressive shift from T helper 1 cell to T helper 2 cell responses (36)
Decrease in T cell function (37–39)
Trans-placental Transfer of Maternal
Antibodies
Immunoglobulin G (IgG) is the dominant immunoglobulin
isotype that crosses the placenta and contributes to maternally
derived passive immunity during early infancy. In healthy
pregnant women, IgG transfer across the placenta begins toward
the end of the first trimester of pregnancy and increases as
pregnancy progresses. IgG concentrations in the fetus are 5–
10% of the maternal levels at 17–22 weeks gestation, 50%
at weeks 28–32, and usually exceed maternal levels by 20–
30% at term (49–52). The transplacental transfer of IgG is
mediated by the neonatal Fc receptors (FcRn), localized in the
syncytiotrophoblast that covers the villous tree of the placenta
(53). FcRn regulates IgG transplacental transfer through binding
to its constant domain and actively transport IgG into the fetal
circulation. Several factors appear to affect the transfer of IgG
across the placenta. IgG subclasses have differential efficiency
of transfer across the placenta, defined as the antibody levels in
the newborn divided by antibody levels in the mother. Based
on studies from the 1990s, IgG1 is the subclass transferred with
the highest efficiency, achieving higher levels in cord compared
with the maternal blood, and this subclass is induced by vaccines
containing protein antigens (54). IgG2 is transferred with the
least efficiency, achieving lower cord than maternal blood levels,
and is the dominant antibody induced by vaccines containing
polysaccharide antigens (53, 55–58). Transfer of antibodies
across the placenta can also be influenced by several clinical
conditions in the mother and some of these health conditions
are more prevalent in certain parts of the world. For instance,
cord IgG levels were lower in infants from women with human
immunodeficiency virus (HIV) infection (59), malaria infection
(60), and hypergammaglobulinemia (61), compared with infants
from women without those conditions, and these conditions
are more prevalent in LMICs. In addition, the potential effect
of toxoplasma and tuberculosis infection on the transfer of
maternal antibodies has not been investigated. Furthermore,
other maternal conditions, that have not yet been investigated,
might also affect the structure of the placenta (e.g., gestational
hypertension, gestational diabetes, smoking) and the transfer of
maternal antibodies.
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Timing of Immunization
A number of factors should be considered when determining
the ideal timing of vaccination in pregnancy including
time-dependent safety when administered at different time
points in gestation, time-dependent efficiency of transplacental
transfer of vaccine-induced antibodies, interference with
infants’ immune response to vaccination and clinical
efficacy/effectiveness (62, 63). Furthermore, the optimal
timing of maternal immunization varies depending on who
is the target for protection and when maximal protection is
desired in the mother and/or the fetus/infant (62). For example,
pregnancy is a well-known risk factor for severe influenza, being
most severe during the third trimester of pregnancy (64, 65).
Therefore, to maximize the protection for the mother, it is best to
administer the influenza vaccine early in pregnancy and ideally
prior to the peak of influenza seasonal activity. If the primary
goal is to protect the infant, as for pertussis, the vaccine should
be administered during a time period in gestation to provide
optimal trans-placental transfer of antibodies, in order to ensure
maximal protection against pertussis disease in early infancy
(66). The risk for premature labor should also be considered as
this population is at an increased risk for severe infections, such
as pertussis and might not benefit from maternal vaccination if it
happens late in gestation (67–69).
Based on the literature review and consultation among
authors, a consensus on priorities for future research related
to factors affecting immunization during pregnancy was
reached (Table 3).
VACCINES CURRENTLY RECOMMENDED
FOR PREGNANT WOMEN
Vaccines currently recommended and used are aimed to protect
against tetanus, pertussis and influenza diseases. Different
vaccine formulations and dosages exist for use in pregnant
women in selected countries in Europe, North America, South
America, and Asia (Table 4).
Vaccines Against Tetanus
The World Health Organization (WHO) recommends that
if a pregnant woman has never received a tetanus-toxoid -
containing vaccine (TT-CV) (e.g., Diphtheria-Tetanus-Pertussis
[DTP], Diphtheria-Tetanus [DT], Tetanus-diphtheria [Td], TT)
or her vaccination status is unknown, she should receive two
TT (or Td) vaccine doses 4 weeks apart during pregnancy, with
the second dose given at least 2 weeks before delivery. Based on
WHO recommendations, five total doses are likely needed for
protection throughout the childbearing years so a third dose is
given 6 months after the second dose, and two additional doses
are recommended to be given during the next 2 years or during
two subsequent pregnancies (73). For women who have received
1–4 TT-CV doses prior to their pregnancy, one TT-CV dose is
recommended during each subsequent pregnancy to a total of
five doses. However, this vaccination schedule and policy has
never been formally evaluated in clinical trials.
TABLE 3 | Consensus on priorities for future research related to factors that
influence the immunogenicity and efficacy/effectiveness of immunization during
pregnancy.
Immune responses of pregnant women to vaccination
1. Immune response (quantity and quality of cellular and antibody immune
responses) of pregnant women to vaccines with potential use in pregnancy in
comparison with non-pregnant women
2. Immune response (quantity and quality of cellular and antibody immune
responses) of pregnant women to vaccines with potential use in pregnancy at
various stages of pregnancy in comparison with non-pregnant women
Trans-placental transfer of maternal antibodies to fetus
1. Create a better understanding of the molecular and cellular basis of maternal
antibody transfer across the placenta, based on currently available vaccines for
use in pregnancy, which would help the design of future vaccines that induce
antibodies with optimal characteristics for transfer to the fetus
2. The induction of different vaccine-induced IgG subclasses should be evaluated
early in the development of new vaccines designed for pregnant women
3. The effect of maternal health conditions on the transfer of vaccine-induced
IgG subclasses should be assessed early in the development of new vaccines
designed for pregnant women. This is especially important for some health
conditions more prevalent in low-middle income countries such as poor nutrition,
human immunodeficiency infection, malaria infection and
hypergammaglobulinemia
Timing of immunization during pregnancy
1. The main target for protection in pregnancy (i.e., pregnant women and/or
infant) and the time in gestation and/or infancy this maximal protection is desired
have to be clearly defined for individual pathogens targeted for immunization
2. The safety of vaccination when administered in different stages during
gestation
3. Time-dependent efficiency of transplacental transfer of vaccine-induced
antibodies (quantity and quality)
4. Time-dependent clinical efficacy/effectiveness (for both term and preterm
infants)
Safety
Several studies have demonstrated TT-CVs to be safe in
pregnancy (74–76). As the current pertussis-containing vaccines
administered in pregnancy are part of multicomponent
formulations that include TT, safety assessments of pertussis-
containing vaccines in pregnancy also provide information on
the safety of the TT component (see below discussion under
pertussis vaccines) (77). Safety was demonstrated even when the
most recent TT-CV was administered within 2 years prior to
vaccination in pregnancy (76).
Immunogenicity
Several studies have shown that following maternal
immunization with TT-CVs, anti-TT IgG is actively transferred
across the placenta, leading to protective levels in the infant
(77–80). Vaccination with TT induces IgG1 (54, 81), which
are efficiently transferred across the placenta. Approximately
80% of maternal antibodies remain present in infants 1 month
after delivery; thus, protection is maintained until a primary
vaccination course is commenced and is maximal during
the most vulnerable period when umbilical infections may
occur (82).
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TABLE 4 | Formulations and dosages of common vaccines to protect against pertussis, and tetanus disease for use in pregnant women in selected countries in Europe,
North America, South America, and Asia.
Vaccine formulation Antigen composition References Selected countries #
Against tetanus
Td (MassBiologics) Diphtheria toxoid: 2 Lf
Tetanus toxoid: 2 Lf
(70) South America: Honduras
Asia: Thailand, Philippines, Malaysia
Africa: Egypt, Gambia, Senegal,
Gabon, Cameron, Botswana
TT adsorbed (Serum Institute of
India)
TT ≥ 5 Lf (71)
Against pertussis
Tdap (Adacel, Sanofi Pasteur) Diphtheria toxoid: 2 Lf
Tetanus toxoid: 5 Lf
PT: 2.5 µg
FHA: 5 µg
PRN: 3 µg
FIM: 5 µg
(70) Europe: Belgium, Spain,
United Kingdom, Italy
North America: Canada,
United States of America
South America: Argentina, Brazil,
Columbia, Chile, Mexico, Uruguay
Asia: Singapore
Africa:
Australia and New Zealand
Tdap (Boostrix, GlaxoSmithKline) Diphtheria toxoid: 2.5 Lf
Tetanus toxoid: 5 Lf
PT: 8 µg
FHA: 8 µg
PRN: 2.5 µg
Against influenza*
Quadrivalent inactivated influenza vaccin Europe: Albania, Belgium, Hungary,
Romania, Russian Federation, Spain,
Sweden, United Kingdom, Italy
North America: Canada,
United States of America
South America: Argentina, Brazil,
Columbia, Ecuador, Bolivia, Mexico,
Uruguay
Australia and New Zealand
Asia: Singapore, Thailand
Africa: South Africa, Algeria
Afluria Quadrivalent (Seqirus)
FluLaval Quadrivalent
(GlaxoSmithKline)
Flucelvax Quadrivalent (Seqirus)
Fluzone Quadrivalent
(Sanofi Pasteur)
Influenza A/Brisbane/02/2018
(H1N1)pdm09-like virus
Influenza A/Kansas/14/2017
(H3N2)-like virus
Influenza B/Colorado/06/2017-like
(Victoria lineage) virus
Influenza B/Phuket/3073/2013–like
virus (Yamagata lineage)
Dosage: Hemagglutinin 15 µG/dose
(each virus)
(72)
Trivalent inactivated influenza vaccine
Fluad (Seqirus) Influenza A/Brisbane/02/2018
(H1N1)pdm09-like virus
Influenza A/Kansas/14/2017
(H3N2)-like virus
Influenza B/Colorado/06/2017-like
(Victoria lineage) virus
Dosage: Hemagglutinin 15 µG/dose
(each virus)
(72)
TT, Tetanus toxoid; Td, Tetanus diphtheria; Tdap, tetanus-diphtheria-acellular-pertussis; Lf, limit of flocculation; PT, pertussis toxin; FHA, filamentous hemagglutinin; PRN, pertactin; FIM,
fimbria 2/3.
*Influenza vaccines compositions are reviewed each year and updated as needed. Composition presented is for 2019-20 influenza season.
#Source: World Health Organization website: https://apps.who.int/immunization_monitoring/globalsummary.
If a Tdap vaccine in pregnancy is being considered to replace
a single dose of TT vaccine in some settings, in order to provide
dual coverage for pertussis and tetanus disease, it is important
to assess the immunogenicity of Tdap in inducing anti-TT IgG
compared with TT or Td formulations. In a small study from
Vietnam, vaccination with Tdap in pregnancy resulted in higher
cord anti-TT IgG levels compared with vaccination with TT,
however, this difference did not persist at 2 months of age (83).
These results are reassuring that replacing TT with Tdap is not
expected to result in inferior immunogenicity against tetanus.
Effectiveness
Both maternal and neonatal tetanus were very common in most
developing countries even into the 1980’s. In 1989, the WHO
called for the elimination of maternal and neonatal tetanus by the
end of the century. At that time, 59 countries reported maternal
and neonatal tetanus. As part of the MNTE program, and along
with safer birth techniques and effective immunization strategies
in children and adults, more than 150 million women were
vaccinated against tetanus during pregnancy. Altogether, these
practices contributed to the elimination of maternal and neonatal
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TABLE 5 | Consensus on priorities for future research related to vaccination
against tetanus during pregnancy.
Vaccines against tetanus disease
Immunogenicity
1. The immunogenicity of different Tdap formulations in pregnancy compared
with TT and Td in countries where TT/Td immunization is given in pregnancy and
Tdap immunization in pregnancy is being considered
2. Immunogenicity of different dosing regimens (number of doses) of tetanus
vaccination during pregnancy, especially in settings where vaccination against
tetanus in childhood is high
TT, Tetanus toxoid; Td, Tetanus diphtheria; Tdap, tetanus-diphtheria-acellular-pertussis.
tetanus in 45/59 countries as of the end of 2018 (84, 85). However,
14 countries, mainly in Africa, still have residual maternal and
neonatal tetanus, highlighting that additional efforts are required
to extend maternal immunization, immunization of children and
adolescents, and other hygienic measures aimed at improved
cord-care. The WHOs most updated goal is to achieve maternal
and neonatal tetanus elimination by 2020 which will be difficult
to achieve (85).
Based on the literature review and consultation among
authors, a consensus on priorities for future research related
to immunization against tetanus during pregnancy was
reached (Table 5).
Vaccines Against Pertussis
Safety
Data on tolerability and safety of pertussis immunization during
pregnancy are reassuring (86). This has been demonstrated with
different Tdap vaccine formulations regardless of the number
of pertussis antigens included in the vaccines (77, 87–96).
Specifically, no increased risk for the development of severe
maternal adverse events (e.g., postpartum endometritis, preterm
delivery, and preterm premature rupture of membranes) or
fetal and neonatal outcomes (e.g., low birth weight, very low
birth weight, small for gestational age, birth defects, and need
for neonatal intensive care unit admission) has been reported.
However, a small increased risk of chorioamnionitis among
Tdap-vaccinated women (relative risk [RR] 1.19, 95% CI, 1.13
to 1.26) was documented in one study (89). In another study
using the Vaccine Adverse Event Reporting System database,
the majority of these women with chorioamnionitis had at
least one risk factor for this complication (97). In addition,
there was limited supportive evidence for a chorioamnionitis
diagnosis on chart review and the risk of preterm birth (a
concern after chorioamnionitis) was not higher among Tdap
recipients. Therefore, the association between this complication
and vaccination during pregnancy has been debated. However,
a recent study reported a small increase of chorioamnionitis in
pregnant women who received Tdap vaccine during pregnancy
with a RR of 1.11 (95% CI: 1.07–1.15); but the absolute
risk was still quite low, at 2.8% (98). Ongoing studies are
currently evaluating the potential association between Tdap
vaccination during pregnancy and chorioamnionitis. In view of
the recommendation to vaccinate against pertussis during each
pregnancy, it has been shown that repeated Tdap vaccinations in
consecutive pregnancies are well-tolerated (76).
Immunogenicity
Vaccination against pertussis in pregnancy has been achieved
using Tdap formulations that include mostly three or five B.
pertussis antigens. Antibodies against all B. pertussis antigens
included in the Tdap vaccine have been shown to reach peak
levels at the end of the second week after Tdap administration
in non-pregnant women of childbearing age, and this peak is
followed by a rapid decline (99). In pregnant women, studies
have shown a significant increase in B. pertussis-specific antibody
levels 1 month after Tdap vaccination, also with a significant
decline, within the first year after maternal vaccination (41, 100,
101). Thus, the persistence of antibodies after a single dose of
Tdap vaccine in pregnancy is short and does not probably ensure
infant protection during consecutive pregnancies. Therefore,
vaccination is currently recommended in every pregnancy.
Vaccination with B. pertussis antigens induces mainly IgG1
antibodies (102, 103) which are actively across the placenta to the
newborn resulting in higher antibody levels in the term newborn
than in the mother (77, 80, 104).
Pertussis toxin is a major virulence factor of B. pertussis
and is potentially responsible for both local and systemic
responses (105). Administration of humanized neutralizing
anti-PT monoclonal antibodies have been shown to abolish
disease manifestations in mice and non-human primates
(106). Maternal immunization with a monocomponent PT
vaccine protected newborn baboons against pertussis following
respiratory challenge with B. pertussis (107). In human, low anti-
PT IgG levels have been associated with high susceptibility to
pertussis (108). However, antibody levels that confer protection
against human pertussis disease have not been defined. In
addition, the number and type of B. pertussis antigens are
required for pregnant women in order to provide clinical
protection to the infant has not been clearly established.
Timing
A study conducted in Thailand showed that vaccination earlier in
pregnancy was associated with higher B. pertussis-specific cord
antibody levels (109). Furthermore, three other studies found
that vaccination during the early third trimester of pregnancy is
associated with higher cord anti-B. pertussis-specific IgG levels
than immunization during late third trimester (110–112). In
addition, one study showed that anti-PT and anti-FHA IgG levels
were higher in cord blood of mothers vaccinated between 13 and
25 weeks gestation compared to those immunized after 25 weeks
gestation (113). This was also observed in preterm infants (114).
In addition, avidity of cord anti-PT IgGwas higher whenmothers
were vaccinated in the early third trimester compared with late
third trimester (115, 116), although this finding was not observed
in a third study (117). Therefore, more data are needed to address
this controversy, including also data from vaccination at earlier
time points in pregnancy. Moreover, because the role of antibody
levels and avidity in protection against pertussis is not conclusive
to date, interpretation of the above studies requires caution.
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TABLE 6 | Consensus on priorities for future research related to vaccination
against pertussis disease during pregnancy.
Safety
1. The association between receipt of Tdap in pregnancy and chorioamnionitis
Immunogenicity
1. Assessment of immune correlates for protection against pertussis disease
(e.g., Bordetella pertussis –specific antibody levels)
2. Bordetella pertussis antigens to be included in pertussis vaccines for maternal
immunization to provide sufficient clinical protection to the infant
3. The need for immunization against pertussis disease in subsequent (3rd or
more) pregnancies.
4. Comparative studies comparing different pertussis vaccine formulations (e.g.,
Tdap vs. aP stand-alone vaccines)
5. Role of previous vaccination of the mother with whole cell or aP vaccines in
the immune response to maternal pertussis vaccination
Timing
1. The effect of timing of vaccination on the function of anti-Bordetella pertussis
antibodies transferred to infants
2. The immunogenicity of stand-alone aP given in different times in pregnancy
Effectiveness
1. Burden of pertussis disease in infancy in low and middle-income countries
2. The effectiveness of maternal immunization program in low and
middle-income countries if pertussis immunization in pregnancy is implemented
3. Assess the eventual role of previous vaccination with whole cell or acellular
pertussis to the mother on vaccine effectiveness
4. Vaccine effectiveness of various Tdap formulations
Tdap, tetanus-diphtheria-acellular-pertussis; aP, acellular pertussis.
Effectiveness
Effectiveness of maternal immunization for prevention of
pertussis in young infants has been well-studied. In England,
vaccine effectiveness was 91% in the reduction of laboratory-
confirmed cases in infants <3 months of age (6), and 93% in
prevention of laboratory-confirmed cases in infants <8 weeks of
age (118). In the US, effectiveness among infants <8 weeks of life
ranged between 85 and 91% (7, 119, 120). In addition, disease was
significantly less severe among infants from vaccinated mothers
(119). In Spain, a case-control study reported VE to be 90%
against laboratory-confirmed pertussis infection in infants <3
months of age (121), while in Australia it was 69% in infants <3
month of age (122). In Brazil, vaccine effectiveness was reported
to be 82.6% for the prevention of clinical pertussis in infants <2
months of age, confirming the success of the maternal pertussis
immunization strategy also in middle-income countries (123).
Based on the literature review and consultation among
authors, a consensus on priorities for future research related
to immunization against pertussis during pregnancy was
reached (Table 6).
Vaccines Against Influenza
Safety
There is an extensive body of evidence in the literature from
both HICs and LMICs that confirm the safety of maternal
influenza vaccination (124–129) [reviewed in (130)]. During the
H1N1 influenza pandemic, data from Sweden and Argentina
found that both AS03-adjuvanted and MF59-adjuvanted -H1N1
influenza vaccines were not associated with increased risk for
low-birth weight or preterm birth or low Apgar score (131, 132).
A meta-analysis including studies using both adjuvanted and
non-adjuvanted influenza vaccines found lower estimates of still
birth after maternal influenza vaccination and no association
with an increased risk of spontaneous abortion (133). However,
a small case-control study in the US over two influenza seasons
(2010–11, 2011–12) found an increased risk of early spontaneous
abortion in a group of women who had received influenza
vaccination in the first trimester of pregnancy, although cases had
other risk factors for spontaneous abortion (older age, pervious
history of spontaneous abortion, smoking); thus the causal
relationship between influenza vaccination and this complication
has been questioned (134). To further support the safety of
influenza vaccination in pregnancy, three Bill & Melinda Gates
Foundation funded studies from South Africa (135), Mali (136),
and Nepal (137), and recent studies and systematic reviews found
that maternal influenza vaccination was not associated with an
increased risk of fetal death, spontaneous abortion, or congenital
malformations (138–141).
Furthermore, concomitant or sequential vaccination with
Tdap and influenza vaccines has also been shown to be safe and
not associated with differences inmedically attended acute events
in pregnant women or adverse birth outcomes (142).
Immunogenicity
Influenza vaccination preferentially induces IgG1 subclass
antibodies (143), and studies have shown increased levels
of influenza-specific hemagglutinin antibodies in neonates
born to women given a monovalent (pH1N1/09) or seasonal
TIV during pregnancy, suggesting efficient transplacental
transfer of influenza-specific antibodies (144–146). Importantly,
seroconversion rates were lower after administration of TIV
in women living with HIV than in women without HIV, and
hemagglutination-inhibiting antibodies (HIA) titers were lower
in HIV-exposed infants (146).
The kinetics of influenza antibody decline in the infant vary
according to the influenza virus and the levels of transferred
antibodies, and thus the duration of protection is not precisely
defined. Some data indicate that maternally-derived HIA against
seasonal influenza viruses have a half-life of approximately
45 days in infants after maternal vaccination and that these
antibodies decline to levels similar to those detected in infants
born to unvaccinated women by 16 weeks of age (147, 148). This
is consistent with higher protection from laboratory-confirmed
influenza disease among infants of vaccinatedmothers during the
first 2–3 months of age (135, 136).
In another study, children born to mothers vaccinated with
an adjuvanted pH1N1 vaccine had antibody levels that remained
elevated above the correlate of protection for adults (HIA titer
> 1:40) up to 5 months (149). However, the interpretation
of influenza immunogenicity studies are complicated as the
correlate of protection against infection in infants has not yet
been established and is likely to be different and higher than
the correlate of protection used for adults (150). This is an area
of controversy, where more research is needed to define the
correlate(s) of protection against influenza disease in infants,
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which is important as currently available pediatric influenza
vaccines are recommended in certain settings from 6 months of
age onwards.
Timing
The optimal timing for maternal influenza immunization has
not been established, and recommendations (e.g., CDC, ECDC,
WHO) allow administration at any time during pregnancy (17,
151, 152). Importantly, since influenza is a seasonal disease
(except in tropical regions, where influenza disease may occur
throughout the year) and the goal of vaccination also serves
to protect the mother, the actual determination of timing may
depend on factors other than optimizing antibody transfer to
the infant. Jackson et al. reported lower antibody levels at birth
in infants of mothers vaccinated earlier during pregnancy (144).
On the other hand, Sperling et al. did not find a significant
association between the gestational age at vaccination and the
seroconversion rates following influenza vaccination in pregnant
women. However, maternal seroconversion rates were slightly
lower in women immunized in the first trimester than in those
given the vaccine in the late third trimester (153). In another
study, a higher level of transplacental transfer of antibodies
was associated with a longer interval between vaccination and
delivery in pregnant women vaccinated against influenza after
20 weeks gestation (146). Blanchard-Rohner et al. showed that
receipt of influenza vaccine at least 2 weeks before delivery
increased umbilical cord HIA titers and seroprotection rates
in newborns (154). Finally, Katz et al. found no significant
differences in influenza HIA titers in cord sera of women
vaccinated early (17–25 weeks gestation) or later (26–34 weeks
gestation) in randomized trials during pregnancy (155).
Efficacy
Influenza can be a severe disease for pregnant women, neonates
and young infants. The severity of infection increases as
pregnancy advances, with the greatest maternal risk occurring
during the third trimester of pregnancy (156, 157). Young infants
on the other hand, have been shown to experience the highest
rates of influenza-related hospitalization (158) and death (159)
among children with influenza infection.
Multiple studies have shown that administration of an IIV
during pregnancy reduces the risk of influenza in pregnant
woman by ∼35–50% (135, 160–162). The efficacy of maternal
influenza vaccination against laboratory-confirmed influenza in
infants below 6 months of age also varies in different trials
conducted at different geographic sites. Efficacy has been 63%
(95% CI, 5–85) in Bangladesh (162), 49% (95% CI, 12–70) in
South Africa (135), 33% (95% CI, 4–54) in Mali (136), and
30% (95% CI, 5–48) in Nepal (137). Efficacy against laboratory-
confirmed influenza in infant was higher in the first 2–3 months
of life and in the range of 70–80% in 2 RCTs from South Africa
andMali (135, 136). Observational studies carried out in the USA
(163, 164) and England (165), reported reductions of laboratory-
confirmed influenza in children born to vaccinated mothers
ranged from 41 to 71%. A recent meta-analysis reported that
maternal influenza vaccination reduced the risk of laboratory-
confirmed influenza infection in infants by 48% (95% CI, 33–59)
TABLE 7 | Consensus on priorities for future research related to vaccination
against influenza disease during pregnancy.
Immunogenicity
1. Correlate(s) of protection against influenza disease in infants
2. The duration of protection conferred by vaccination in pregnancy in infants.
This needs to take into account seasonality in different settings (tropical regions
vs. temperate climate regions)
3. Evaluation of more immunogenic influenza vaccines in pregnant women to
optimize antibody transfer to their infants
Efficacy/Effectiveness
1. The development of more immunogenic influenza vaccines to optimize
protection of young infants
2. Evaluate vaccine-efficacy against non-specific (all-cause) lower-respiratory
tract infections
(166). In addition, maternal influenza vaccination was associated
with a reduction in all-cause severe pneumonia in infants. An
analysis of three Bill &Melinda Gates foundation -funded clinical
trials conducted inNepal, Mali and South Africa including 10,002
mothers and 9801 live-born eligible infants concluded that the
pooled incidence rate of severe pneumonia up to 6 months
of age was 20% lower in infants born to women vaccinated
with IIV compared with infants born to women unvaccinated
in pregnancy (incidence rate ratio [IRR]: 0.80; 95% CI: 0.66–
0.99) (167). However, it should be noted that few of these cases
had influenza identified despite testing suggesting that influenza
vaccination during pregnancy might have benefits beyond the
prevention of classical influenza disease.
The efficacy of IIV in pregnancy in the prevention of maternal
and infant influenza disease varies depending on the setting
as well as the match of the vaccine utilized to circulating
influenza strains. The majority of efficacy data are derived from
studies performed in LMICs when compared to HICs. While
influenza disease is seasonal in countries with temperate climates
(e.g., Europe, North America), there is no seasonal pattern in
tropical countries.
Altogether, current data on safety, immunogenicity, and
efficacy of maternal IIV vaccination, for the pregnant women and
their infants has resulted in pregnancy as a potential indication
in the vaccine label by the European Medicines Agency as of
July, 2019 (168). In Australia, categorization of influenza vaccines
given during pregnancy has changed to category A (no proven
harmful effects) (169). Other individual countries will have their
own considerations.
Based on the literature review and consultation among
authors, a consensus on priorities for future research realted
to immunization against influenza during pregnancy was
reached (Table 7).
IMPACT OF MATERNAL IMMUNIZATION
ON INFANTS’ IMMUNE RESPONSES TO
IMMUNIZATION
High levels of vaccine-induced maternally-derived antibodies
have the potential to reduce the infants’ humoral immune
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responses by inhibiting antibody generation after the infant’s own
vaccination, leading to lower antibody levels/titers later on in
the infant (170, 171). This phenomenon is called “interference”
or “blunting” and has been described for the same vaccine
antigens used by mother and infant, as well as for conjugated
vaccines administered in infancy (172). Data from the 1990s
showed that the administration of Haemophilus influenzae type
b (Hib) polysaccharide or Hib conjugated vaccines in pregnant
women was associated with mild inhibition of infants’ immune
responses to Hib conjugated vaccines (173). Differences in
antibody responses in infants born to vaccinated compared
with unvaccinated mothers were minimized following the
booster dose. An analysis of the genetic repertoire of the light
chain of antibodies to the polysaccharide vaccine demonstrated
no differences between infants born to immunized women
compared with non-immunized women (174). There was no
evidence of inhibition of “priming” of the infants’ immune
system to Hib in these studies.
Tetanus-Containing Vaccines
Most data on the impact on TT-CVs in infancy are derived
from studies that used Tdap formulations in pregnancy and
measured anti-TT IgG levels after infant vaccination. These
studies found inconsistent results. Some showed significantly
lower anti-TT levels after primary immunization in infants
born to Tdap-vaccinated women compared to infants from
unvaccinated women whilst other studies showed equal or even
significantly higher anti-TT levels in infants born to Tdap-
vaccinated women compared to infants from unvaccinated
women (77, 80, 175–177). However, this inhibition found in some
studies did not result in a reduction of the percentage of infants
with seroprotective anti-TT antibody levels.
The effect of different TT-CV formulations used in pregnancy
(Tdap vs. TT/Td) on immune responses to tetanus-containing
vaccines in infancy is of importance in countries where a
replacement of the existing tetanus vaccination program by
a Tdap vaccination program is being considered. A small
study in Vietnam reported higher anti-TT levels after primary
immunization with tetanus-containing vaccines in infants born
to Tdap-vaccinated pregnant women compared to infants born
to TT-vaccinated pregnant women (83). A study from Canada
found no difference in anti-TT levels after primary and booster
immunization in infants born to Tdap-vaccinated pregnant
women when compared to Td-vaccinated pregnant women
(104). These data suggest that Tdap, when compared to TT or
Td in pregnancy, is not associated with lower anti-TT IgG levels
after primary and booster immunization with tetanus-containing
vaccines in infancy. However, in order to provide a definite
conclusion, formal studies should be conducted with the aim to
address this question as the primary outcome.
Several vaccines are conjugated to TT as a carrier protein
(e.g., Hib vaccines, meningococcal vaccines) and thus vaccine-
induced immune responses to these vaccines in infant born
to Tdap-vaccinated pregnant women might also be affected.
Hib anti-polyribosylribitol phosphate (PRP) levels were higher
after primary immunization with Hib TT-conjugated vaccine
in infants born to Tdap-vaccinated pregnant women when
compared to infants of unvaccinated mothers (175, 178).
One study found no differences between anti-Men C antibody
levels after primary immunization with meningococcal C TT-
conjugated vaccine in infant born to Tdap-vaccinated when
compared to unvaccinated pregnant women (178). More studies
are needed to investigate the potential effect of tetanus-
containing vaccines administered in pregnancy on infants’
immune response to vaccines conjugated to TT.
Pertussis Vaccines
Studies have shown that Tdap immunization in pregnancy is
associated with decreases in humoral immune responses to
infants’ immunization with acellular pertussis (aP) containing
vaccines. Several studies describe significantly lower anti-PT
IgG levels in infants born to Tdap-vaccinated pregnant women
after the completion of primary immunization, while results
were less consistent after booster immunization (77, 80, 83, 104,
175–177). Results from these studies showed also interference
to other pertussis antigens (FHA, pertactin, fimbria 2/3) after
primary immunization while results were inconsistent after
booster immunization.
Most studies investigating the potential modification of
infants’ immune responses to aP vaccines have been performed
in HICs, with the exception of one study from Vietnam (83,
177). It is important to note that the degree of reduction in
immune responses to wP infant vaccines might be different than
to immunization with aP infant vaccines. The use of wP vaccines
but not aP vaccines was associated with a substantial reduction
in the subsequent infant antibody response to PT in infants
born to mothers with high levels of maternally-derived anti-
PT antibodies (179). In another study, there was no correlation
between low anti- B. pertussis antibody levels at delivery in infants
born to unvaccinated women and their anti-B. pertussis antibody
levels after wP vaccination (180).
A recent study reported that Thai infants born to unvaccinated
mothers and subsequently vaccinated with wP vaccines, had
higher anti-B. pertussis-specific antibody levels after primary
and booster vaccination than infants born to women vaccinated
with Tdap during pregnancy and vaccinated with wP vaccines
(181). In addition, infants born to women vaccinated with
Tdap in pregnancy and vaccinated with wP vaccines had
lower anti- B. pertussis-specific antibody levels after vaccination
when compared with infants born to vaccinated mothers and
vaccinated with aP vaccines (181).
Altogether, these results indicate that infants born to Tdap-
vaccinated mothers might be at increased risk for pertussis
later in life. However, surveillance data from the US and UK
did not demonstrate any increase in the number of pertussis
cases later in infancy after the introduction of the maternal
immunization program suggesting a possible lack of clinical
significance of this interference (6). Interpretation of interference
to wP immunization is more challenging in LMICS compared
with HICs due to the lack of comprehensive surveillance systems
in some countries (182).
Because vaccines against pertussis that are currently used in
pregnancy also contain dT, interferencemight also be extended to
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diphtheria-containing vaccines administered in infancy. Data on
this respect have been inconsistent, with some studies reporting
significantly lower anti-diphtheria toxin antibody levels in infants
born to Tdap-vaccinated women when compared to infants born
to unvaccinated women, while other studies did not report this
effect (77, 80, 83, 104, 175–177). It is also important to note
that Tdap immunization in pregnancy, likely due to anti-DT
antibodies, is associated with lower anti-pneumococcal capsular
polysaccharide levels after immunization with pneumococcal
vaccines (PCVs) conjugated to a non-toxic diphtheria toxin
mutant (CRM197), although, this did not result in lower
seropotection levels for most serotypes (175, 183). Surveillance
will be key to assess whether this interference has any impact on
pneumococcal disease burden.
If long-term surveillance data would indicate that interference
is clinically significant, strategies to mitigate the effect of
interference will need to be evaluated. Timing of vaccination
in pregnancy is an important modifiable variable and should
be investigated. Delaying primary infant vaccination is another
approach and has been recently implemented in The Netherlands
in infants born to Tdap-vaccinated mothers. In addition, stand-
alone pertussis vaccines (without TT, dT) should be investigated
in clinical trials (184) as these vaccines might lessen the
concern of interference to TT and DT components and vaccines
conjugated to those proteins as carrier proteins.
Influenza Vaccines
Data on the potential impact of maternal influenza immunization
on the immune response of infants to their immunization against
influenza are scarce as influenza vaccines are administered
in infants older than 6 months, when most maternally-
derived antibodies already have waned from infant’s circulation.
Earlier studies performed to assess immunogenicity of influenza
vaccination in infants younger than 6 months old found that
post vaccination seroprotection rates (titer ≥ 1:40) were higher
in infants who received IIV at 6 months of age when compared
to infants who received vaccination during 6–12 weeks of age
(185). Another prospective, open-label study in which 2 doses
of a TIV were administered to healthy infants aged 3–5 months
found a 4-fold increase in antibody titers to be significantly more
common in children who were seronegative (pre-vaccination
titers <1:8) at enrollment than in those with pre-vaccination
titers ≥1:8 (186).
Mechanism of Interference
Mechanism of interference between maternally-derived
antibodies and infant’s immune responses to subsequent
immunizations has not been fully explored (187). Some proposed
mechanisms include inhibition of B cell response to vaccine
antigens through epitope masking by maternal antibodies (172)
and neutralization of vaccine antigens (187, 188). Inhibition of
B cell activation through crosslinking of FcγRIIB to the B-cell
receptor on B cells has also been proposed. Specifically, vaccine
antigen–antibody complexes cross-link the B-cell receptor
(which recognizes the variable region of the antibody) with the
Fcγ receptor IIB (which recognizes the constant region of the
antibody), thus inhibiting antigen specific B-cell activation (189).
Furthermore, vaccine antigen-antibody complexes removal by
macrophages has been suggested although no evidence has been
provided to support this hypothesis. Using influenza vaccination
in pregnancy as a model, it was recently shown in mice that
maternal antibodies do not prevent activation of B cells or the
formation of the germinal center. However, maternal antibodies
reduced the number of B cells that differentiate to plasma cells
and memory B cells (190). Whether these results apply to human
infants and other antigens needs to be determined. Finally,
while B cell responses are inhibited in the presence of maternal
antibodies, scarce data support that T cell responses are detected
in the presence of maternal antibodies (191).
IMPACT OF MATERNAL IMMUNIZATION
ON THE NEONATAL IMMUNE SYSTEM
The impact of maternal vaccination on the fetal/neonatal
immune system, beyond the trans-placental transfer of IgG, has
not been well-studied. In utero priming of the fetal immune
system after vaccination against influenza in pregnancy has been
reported. IgM antibodies against influenza vaccine antigens were
detected in nearly 40% of cord blood specimens of newborns
born to women vaccinated with IIV in pregnancy (192). As IgM
antibodies do not cross the placenta, these antibodies are of fetal
origin. In addition, using MHC tetramers, HA-specific CD4+ T
cells were also detected in cord blood, further supporting the “in
utero priming hypothesis” after maternal immunization (192).
Additional studies are needed to further assess the possibility
of priming of fetal immune system to B. pertussis antigens after
immunization in pregnancy.
Based on the literature review and consultation among
authors, a consensus on priorities for future research related to
the effect of immunization during pregnancy on infants’ immune
responses was reached (Table 8).
FUTURE VACCINES FOR IMMUNIZATION
DURING PREGNANCY
In addition to tetanus containing, pertussis containing and
influenza vaccines currently used in pregnancy, multiple novel
GBS and RSV candidate vaccines are under development for
use in pregnant women (193). Infection with other pathogens
(e.g., dengue virus, Zika virus) during pregnancy is associated
with a significant risk of adverse fetal outcome (194–196), and
thus vaccines developed with the goal to prevent these congenital
infections might prove to be an important preventative strategy.
However, these not part of this consensus paper and are reviewed
elsewhere (197, 198).
Group B Streptococcus Vaccines
GBS colonization in pregnant women is associated with an
increased risk of premature birth, birth asphyxia, stillbirths,
and invasive GBS disease in newborns during the first week of
life (early-onset disease, EOD). Newborns of mothers colonized
with GBS are at higher risk of developing meningitis and sepsis
(199). Although intrapartum antibiotic prophylaxis is effective in
Frontiers in Immunology | www.frontiersin.org 12 June 2020 | Volume 11 | Article 1282
Abu-Raya et al. Consensus Statement on Immunization During Pregnancy
TABLE 8 | Consensus on priorities for future research related to the impact of
maternal immunization on in-utero immune system and infants’ immune
responses to immunization.
Infants’ immune responses to TT-containing vaccines
1. The impact of anti-TT maternally-derived antibodies on infants’ responses to
tetanus-containing vaccines administered during infancy and whether this is
affected by vaccine formulation given to pregnant women (TT vs. Td vs. Tdap)
Infants’ immune responses to DT-containing vaccines
1. The impact of anti-DT maternally-derived antibodies on infants’ responses to
vaccines conjugated to DT mutants as a carrier protein (e.g.,
CRM197-conjugated vaccines) administered during infancy
Infants’ immune responses to pertussis vaccines
1. Clinical significance of interference to pertussis immunization in pregnancy
2. If interference is found to be clinically significant, modifiable factors that can
mitigate interference need to be explored
3. The effect of timing of vaccination during pregnancy on interference
4. The impact of a stand-alone pertussis vaccine (no TT, DT) on infants’ immune
responses to pertussis vaccine administered during pregnancy
General
1. The mechanism of inhibition of maternally-derived antibodies on infants
immune responses to their vaccination
2. The effect of maternally derived antibodies on infant T cell responses
3. The potential priming of the fetal immune system to vaccine antigens after
immunization during pregnancy and its effect on training neonatal immune
system
TT, Tetanus toxoid; Td, Tetanus diphtheria; Tdap, tetanus-diphtheria-acellular-pertussis;
DT, Diphtheria toxoid.
preventing GBS EOD, it is not effective in preventing late onset
disease (LOD,>7–90 days of age) and it might be associated with
dysregulation of the infants’ gastro-intestinal microbiome (200).
Importantly, identification and treatment of colonized mothers
can be difficult and expensive, particularly in LMICs, where the
incidence of neonatal invasive GBS disease is higher compared to
HICs (201). Development of GBS vaccines for immunization in
pregnancy and its use in LMICs has been identified as a priority
by the WHO (202).
Vaccines based on the capsular polysaccharide of the most
common GBS strains conjugated to a carrier protein (e.g.,
TT or a non-toxic mutant of diphtheria toxin) are the most
studied candidate vaccines (203). A recent systematic review
of clinical trials evaluating candidate GBS vaccines concluded
that these candidate GBS vaccines are safe and well-tolerated in
pregnant women and non-pregnant adults, may reduce vaginal
colonization and induce antibody titers against the GBS strains
included in the vaccine at a significantly higher level than that
detected in unvaccinated controls (203). Moreover, antibodies
induced by GBS vaccines showed high longevity and were able
to promote GBS opsonophagocytosis in vitro (203).
Several challenges for the development of GBS vaccines for
maternal immunization remain unsolved. There are only 10
known GBS serotypes, of which 6 are associated with 98% of all
described strains that cause invasive disease and even a trivalent
vaccine (Ia, Ib, and III) would provide coverage for 80% of all
global invasive disease cases (204). The prevalence of different
GBS serotypes may vary in different countries, however, the
most common serotypes (Ia, Ib, II, III, IV, and V) are dominant
globally, with only Asia reporting a slightly higher proportion of
cases due to one additional serotype (VII) (205). The distribution
of serotypes responsible for early and late -onset GBS disease also
varies, with the most common serotypes being III and Ia (206).
Correlates of protection for the different GBS serotypes against
the various clinical conditions associated with the pathogen
(i.e., colonization, maternal and infant disease) are not precisely
defined (207), and these correlates may vary by serotype (207).
Furthermore, transplacental transfer of antibodies might be
affected by the characteristics of the vaccine (conjugated vs.
unconjugated), the carrier protein used for conjugation, and the
presence of underlying diseases in the mother which can reduce
transfer, such as HIV infection (208).
Phase 1b/2 clinical trials have shown that vaccination of
pregnant women with a trivalent GBS vaccine (serotype III, Ia,
and Ib conjugated to CRM197) induces anti-GBS antibodies
that are transferred to the newborn at delivery (208–210). Other
phase 1/2 clinical trials are currently evaluating multi-serotype
vaccines, including a hexavalent vaccine (serotypes Ia, Ib, II, III,
IV, V) that cover 98% of strains associated with invasive GBS
disease in both a non-pregnant population (NCT03170609) and
in pregnant women (NCT03765073).
Finally, the clinical effectiveness of GBS vaccines in pregnant
women and neonates has not been determined. Considering
the relatively low incidence of invasive GBS disease, especially
in HICs, the pathway of licensure of a GBS vaccine targeted
at pregnant women with the main objective of protection of
their infants against early and late-onset invasive GBS disease
is likely to require an alternate approach than conventional
efficacy trials. This would include demonstrating the safety of
the vaccine in pregnant women (∼3,000–4,500 participants), and
benchmarking their immune responses to a serological endpoint
associated with reduced risk for invasive GBS disease. Studies are
currently underway in LMICs and HICs, which are investigating
the association of maternal-derived serotype-specific IgG (using
a standardized assay) and threshold associated with 80–90% risk
reduction for invasive GBS disease.
As current GBS vaccines that are under development are
conjugated to TT or the DTmutant CRM197, it will be important
to investigate whether these vaccines given to pregnant women
may result in interference to infant vaccines conjugated to
these carrier proteins and given in infancy (e.g., PCV, Hib,
and Meningococcal vaccines). Current evidence suggests that
CRM197-conjugated GBS vaccine administered in pregnancy did
not affect infants’ immune responses to PCVs (211).
Respiratory Syncytial Virus
RSV is the most common cause of severe lower respiratory
tract infections (LRTIs) in young children worldwide with
a disproportionate high burden of disease in LMICs (e.g.,
higher case-fatality rate) (212). Preterm infants and infants
with underlying severe chronic heart or lung disease are at
higher risk of severe RSV infection, leading to hospitalization
and death. A monoclonal antibody directed against the RSV
fusion (F) protein has been administered to high-risk populations
to prevent RSV-related morbidity in infants in high-income
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countries (213, 214). However, this strategy is highly expensive
and its effectiveness varies ranging between 48 and 96%
in the prevention of RSV-related hospitalization in high-risk
children (215, 216). In addition, overall more healthy children
are infected with RSV each year than high-risk children. A
novel prolonged half-life anti-RSV monoclonal antibody may
prove to be more effective in preventing RSV disease in
infancy (217).
Recently, several new vaccines, including live-attenuated,
gene-based vector vaccines, and particle-based vaccines, have
been developed and found to be safe and well-tolerated in the
non-pregnant population (11, 193). Hence, as most of the cases
of severe RSV infection occur in the first 3 months of life,
it is unlikely that infants’ immunization can provide sufficient
and timely protection. Therefore, maternal immunization is
considered as a suitable strategy for prevention of RSV disease
in young infants (11, 218).
Studies on RSV-F protein in pregnant women have shown
that these vaccines are safe and immunogenic in pregnant
women (219, 220). The use of these RSV vaccines in healthy
pregnant women is further supported by evidence that maternal
RSV neutralizing antibodies are efficiently transferred from the
mother to the newborn, with levels at delivery that are similar
or higher in the cord blood compared with the maternal blood
at delivery (219, 220). However, the association between higher
cord RSV neutralizing antibody levels and the reduction of
risk for RSV LRTI in the infant is not clear, and no definitive
correlates of protection have been defined so far (221–223).
Vaccines containing the RSV-F protein in pregnant women have
shown that these vaccines are safe and immunogenic in pregnant
women (219, 220).
A phase 3, randomized, placebo controlled trial including
4,636 pregnant women has been conducted in 11 countries
with a RSV-F nanoparticle alum-adjuvanted vaccine showed that
protection against RSV LRTI hospitalization was noted (44.4%
vaccine efficacy, 95%CI: 19.6 to 61.5), but the primary study
endpoint (per protocol analysis) for reduction of medically-
significant RSV LRTI (39% vaccine efficacy; 97.5%CI:−1 to 63.7)
was not met (albeit the 95% CI been 5.3 to 61.2) (224). This is the
largest study so far to evaluate a vaccine primarily designed for
use in pregnant women.
Multiple factors could have affected the outcomes measured
in this first immunization study of a RSV vaccine in pregnancy.
Pregnant women were vaccinated during 28–36 weeks gestation,
and efficiency of transfer of anti-RSV antibodies were found to
be higher in women vaccinated <30 weeks GA compared with
women vaccinated ≥30 weeks GA. In addition, vaccine efficacy
varied in different settings, being higher in middle-income
countries (compared with HICs). Mathematical modeling can
help predict women and infants who are expected to benefit the
most from RSV vaccines. This could be achieved by defining
women who are expected to deliver in RSV season and the
preferred timing of vaccination to optimize protection in those
infants. Ideal timing of vaccination could be predicted based on
the kinetics of antibody response in mothers, the efficiency of
antibody transfer and their estimated half-life, and duration of
infants’ exposure to seasonal RSV.
TABLE 9 | Consensus on priorities for future research related to vaccines against
respiratory syncytial virus and Group B Streptococcus diseases during pregnancy.
Group B Streptococcus vaccines
1. The epidemiology of GBS disease in early life and risk factors for GBS disease
in diverse geographic settings
2. Ideal composition of GBS vaccines to achieve highest protection against early
and late onset GBS disease
3. Correlate(s) of protection against early and late onset GBS disease
4. Whether GBS vaccines given to pregnant women interfere with vaccines given
in infancy and conjugated to TT and DT as carrier proteins
5. Effectiveness of GBS vaccines administered during pregnancy in reduction of
early and late onset GBS disease
Respiratory syncytial virus
1. Definition of ideal timing of vaccination in pregnancy to achieve highest
immunogenicity in infants
2. Mathematical modeling to inform clinical trials design to better define infants
who will benefit the most from vaccination during pregnancy
3. Correlate(s) of protection against RSV disease in infancy
4. Epidemiology of RSV disease in 1st and 2nd years of life in offspring of
mothers vaccinated during pregnancy
GBS, Group B Streptococcus; TT, Tetanus toxoid; DT, Diphtheria toxoid; RSV, Respiratory
Syncytial Virus.
Based on the literature review and consultation among
authors, a consensus on priorities for future research related
to immunization during pregnancy against GBS and RSV was
reached (Table 9).
INDUCTION OF VACCINE-SPECIFIC
IMMUNITY IN BREASTMILK
There is a paucity of information on the induction of antibodies
in breastmilk following vaccination in pregnancy (225). Anti-
B. pertussis secretory immunoglobulin A (sIgA) antibodies were
detected in colostrum and in breast milk up to 8 weeks after
delivery from women vaccinated with Tdap during pregnancy
(226, 227). However, the clinical significance of these elevated
B. pertussis-specific antibody concentrations in breastmilk has
not been studied. A study from Bangladesh showed that
vaccination with TIV in pregnancy induced influenza-specific
sIgA levels in breastmilk for at least 6 months postpartum. In
addition, breastfeeding was associated with a decrease in episodes
of respiratory illness with fever in infants born to mothers
vaccinated against influenza during pregnancy (228). A study
from South Africa found that breastmilk sIgA against GBS was
associated with lower risk for GBS LOD in young infants (229). In
a study fromNepal, breastmilk RSV IgG levels, but not IgA levels,
were lower in mothers of infants with RSV acute respiratory
infection (230). While these studies report potential association
between breastfeeding and reduction in disease risk, the casual
relationship has not been confirmed.
Based on the literature review and consultation among
authors, a consensus on priorities for future research related to
the effect of immunization during pregnancy on the induction of
vaccine-specific immunity in breast milk was reached (Table 10).
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TABLE 10 | Consensus on priorities for future research related to induction of
vaccine-specific immunity in breast milk.
1. The additional role of breastfeeding in protection against clinical disease in
infants born to mothers vaccinated against influenza, RSV and GBS during
different phases of breastfeeding (colostrum, after 2–3 months of breastfeeding,
etc.)
2. The additional role of breastfeeding in protection against clinical disease in
infants born to mothers vaccinated against pertussis in settings where vaccine
effectiveness is not optimal
3. Mechanisms of protection against respiratory pathogens through breastmilk
ACCEPTANCE AND STRATEGIES FOR
INCREASING UPTAKE OF VACCINES
The acceptance and coverage of immunization against tetanus
during pregnancy in LMICs have been historically high
(231). Despite recommendations by multiple health authorities
worldwide, maternal immunization with influenza and pertussis
vaccines has not been as widely accepted by healthcare workers
or the general public, including pregnant women (232). Coverage
remains suboptimal in many countries where recommendations
for maternal immunization with influenza and pertussis vaccines
have been in place for several years. In the US, influenza and
pertussis vaccines have been recommended for all pregnant
women since 2004 (233) and 2011 (234), respectively. However,
during the 2017–2018 influenza season, only 49.1% of pregnant
women received the influenza vaccine during the peak influenza
season (235). During the same months, maternal Tdap uptake
was only slightly higher (54.4%). Finally, the receipt of both
vaccines was documented in only 32.8% of pregnant women
(235). In the UK, where pertussis vaccine has been offered to
all pregnant women since October 1, 2012, coverage during the
period from April to June 2018 was 68.2% (236). In the European
Union, although 90% of countries recommend vaccination
against influenza for pregnant women, coverage was generally
low in 2014–2015, with half of the countries reporting uptake
of <10% (237). In France, during the 2015–16 season vaccine
coverage was only 7.4% (238). In Switzerland influenza and
pertussis immunizations in pregnancy have been recommended
since 2009 and 2013, respectively. Yet, in a study performed in
women who gave birth between 2013 and 2017, only five (3%) of
172 mothers had received both pertussis and influenza vaccines
during pregnancy, 15 (9%) only against pertussis and 12 (7%)
only against influenza (239).
Several factors can explain the poor compliance with the
official recommendations. A recent literature review documented
25 individual patient-level and 24 healthcare provider-level
barriers to maternal immunization uptake (240). Among the
patient-identified barriers, concerns regarding safety for the
mother or the newborn were very common and were cited in
6.4–71% and 2.9–77.0% of studies, respectively. Other vaccine
and disease-related factors included concerns about vaccine
efficacy, the belief that the disease was not sufficiently severe
to require prevention, and the idea that healthy people did not
need immunization. Moreover, several structural and logistical
TABLE 11 | Consensus on priorities for future research related to acceptance and
strategies for increasing uptake of vaccines administered during pregnancy.
To identify strategies to increase tetanus vaccine coverage during pregnancy in
low-middle income countries
The region and cultural specific approaches for implementation of vaccinations
during pregnancy and their acceptance
The barriers to high maternal immunization uptake in specific populations.
The need of adequate education of health-care providers on maternal
immunization and establishing a consensus on a minimum curriculum to be
achieved during (para)medical education
The need of global information and awareness-raising campaigns
How to best inform pregnant women about new vaccines
The effectiveness of different strategies to increase influenza and pertussis
vaccination coverage in pregnant women in different regions and cultures
To analyze similarities and differences in knowledge and attitudes to influenza
and pertussis vaccination during pregnancy
barriers were identified. Lack of insurance coverage, limited
access or transportation, and the difficulty of finding a provider
for vaccine administration were reported. Finally, social,
psychological factors, and insufficient knowledge were listed
repeatedly. Among the provider-level barriers, poor knowledge
of the recommendations for immunization of pregnant
women, financial concerns (inadequate reimbursement,
payment, and/or complexity of billing), and inability to
order, obtain and store vaccines. Globally, the lack of
knowledge of vaccine recommendations seems to be the
most important barrier for both health care workers (HCWs)
(241–246) and pregnant women (247–252). HCWs in contact
with pregnant women frequently have little experience in
vaccines and therefore do not offer vaccinations to pregnant
women (239, 253).
To overcome barriers to maternal immunization,
both provider-focused and mother-focused interventions
have been suggested, with a significant improvement in
vaccine uptake has been evidenced in several cases (253).
Suggested provider-focused interventions were notifying
the provider of the vaccination status of pregnant women,
establishing standing orders authorizing nursing staff to
administer the vaccines without a medical consultation,
giving provider feedback by reporting the vaccination rates
of other institutions, and providing education to improve
the knowledge and attitudes of HCWs toward vaccination
in pregnancy. However, education of HCWs alone is
probably ineffective if parental vaccine hesitancy is not
addressed simultaneously.
Multiple educational efforts involving all HCWs who deliver
care to pregnant women and the pregnant women themselves
can yield positive results (254). This observation seems to have
been confirmed by a study by Chamberlain et al., who showed
that when obstetricians and women became familiar with the
recommendation to promote and receive the influenza vaccine
during pregnancy, the percentage of women who refused to
be vaccinated declined from 88.9% in 2004 to 64.2% in 2011
(254). To overcome barriers in pregnant women, studies were
planned to disseminate education and promotion of materials
specifically for pregnant women by mass media campaigns
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via the internet, posters and leaflets, lectures and workshops,
and personalized reminders and recall system (254). Integrating
maternal immunization into routine obstetric care, with vaccine
availability within the obstetrical setting, appears to be the
best method of improving maternal immunization as well as
subsequent childhood vaccine uptake (255).
Based on the literature review and consultation among
authors, a consensus on priorities for future research related
to acceptance and uptake of vaccines administered during
pregnancy was reached (Table 11).
CONCLUSIONS
Pregnant women, their newborns and young infants are
vulnerable to serious and potentially fatal infections. The new
WHO goals aim to increase rates of live births and improve
antenatal care for pregnant women (256), and vaccination
in pregnancy is one strategy to improve health of pregnant
women and their offspring. Safe and effective vaccines are
already available against some diseases (tetanus, pertussis and
influenza) for use during pregnancy, and these vaccines have
the potential to prevent significant infectious disease morbidity
and mortality in both the mothers and their offspring. In
addition, new vaccines (e.g., RSV, GBS) are currently under
development and are being tested in clinical trials, to be licensed
and used in pregnant women. Following literature review
and a consultation amongst experts in the fields of infectious
diseases, vaccination and immunization during pregnancy,
several gaps in knowledge and priorities for research were
identified and are proposed (Tables 3–11). Addressing these
priorities in future research has the potential to increase our
understanding in different aspects of immunization during
pregnancy and optimize protection for both the mother and
the infant.
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